Týdenní vs dvoutýdenní aplikace cetuximabu v léčbě metastatického kolorektálního karcinomu –⁠ aktuální klinická data

1. Nolting A, Fox FE, Kovar A. Clinical drug development of cetuximab, a monoclonal antibody. In: Meibohm B (ed). Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies In Drug Development. Weinheim, Germany: Wiley VCH Verlag GmbH & Co. KGaA 2006 : 353 –⁠ 371.

2. Fracasso PM, Burris H 3rd, Arquette MA et al. A phase 1 escalating single‑dose and weekly fixed‑dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13(3): 986 –⁠ 993.

3. Tabernero J, Ciardiello F, Rivera F et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two‑part pharmacokinetic/ pharmacodynamic phase I dose‑escalation study. Ann Oncol 2010; 21(7): 1537 –⁠ 1545.

4. Martin‑Martorell P, Rosello S, Rodriguez ‑⁠ Braun E et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008; 99(3): 455 –⁠ 458.

5. Pfeiffer P, Nielsen D, Bjerregaard J et al. Biweekly cetuximab and irinotecan as third‑line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19(6): 1141 –⁠ 1145.

6. Shitara K, Yuki S, Yoshida M et al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild‑type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest New Drugs 2012; 30(2): 787 –⁠ 793.

7. Kang MJ, Hong YS, Kim KP et al. Biweekly cetuximab plus irinotecan as secondline chemotherapy for patients with irinotecan ‑⁠ refractory and KRAS wild‑type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs 2012; 30(4): 1607 –⁠ 1613.

8. Jensen BV, Schou JV, Johannesen HH et al. Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5 -⁠ FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. J Clin Oncol 2010; 28 (Suppl): 7.

9. Bouchahda M, Macarulla T, Liedo G et al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011; 28 (Suppl 1): S253 –⁠ S258.

10. Roca JM, Alonso V, Pericay C et al. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer. Chemotherapy 2010; 56(2): 142 –⁠ 146.

11. Brodowicz T, Ciuleanu TE, Radosavljevic D et al. FOLFOX4 plus cetuximab administered weekly or every second week in the first‑line treatment of patients with KRAS wild‑type metastatic colorectal cancer: a randomized phase II CECOG study. Ann Oncol 2013; 24(7): 1769 –⁠ 1777.

12. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to bio­marker status of cetuximab plus FOLFOX ‑⁠ 4 as first‑line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22(7): 1535 –⁠ 1546.

13. Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first‑line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29(15): 2011 –⁠ 2019.